Agilon Health Adjusts To Recovery Phase, Analyst Is Cautious On Near-Term Fundamentals

JP Morgan analyst updates estimates for Agilon Health, Inc. based on Q4 results and management’s outlook for recovery and growth in 2025-2027.

Latest Ratings for AGL

DateFirmActionFromTo Dec 2021Deutsche BankMaintainsBuy Nov 2021SVB LeerinkMaintainsOutperform Oct 2021JefferiesInitiates Coverage OnBuy

View More Analyst Ratings for AGL

View the Latest Analyst Ratings

read more